India Glycols Ltd

📊 India Glycols' Ennature Biopharma: Future Guidance – APIs, Nutraceuticals & Biopolymers

- Ennature Biopharma: demerged integrated natural ingredients platform (3 businesses)

- API business targets one new API per year, deeper regulated markets

- Leadership in Thiocolchicoside, Colchicine, Nicotine, Vinpocetine

- Branded Nutraceuticals primary growth driver with clinically validated ingredients

- Nutraceuticals target 6-8 branded ingredients with expanded US, Europe, Asia distribution

- Key strategies: strengthen branded portfolio, establish US office, expand into Korea, Europe, Taiwan

- Biopolymer (Guar) to scale dietary fibre applications, value-added derivatives

- API outlook: gain share in Nicotine, Thiocolchicoside, establish NRT presence

- Biopolymer focus on higher-value product mix and dietary-fibre market

- Differentiation: IP, clinical evidence, plant-based phyto-actives, EU-GMP, US-FDA